Cann Group Limited
Developing a world-class, Australia-focused medicinal cannabis operation
cann-group-header-home1.jpg

HOME

Developing medicinal cannabis products to improve quality of life for Australian patients

Welcome to Cann Group

Cann Group’s vision is to provide access to a range of medicinal cannabis products for patients in Australia and globally. Cann’s expertise and partnerships support the rapid growth of globally competitive Australian research, cultivation and production capabilities.

Cann was the first Australian company to receive a licence and subsequent permit from the Federal Government to cultivate medicinal cannabis in Australia.

Cann aims to cultivate and manufacture a range of medicinal cannabis products for patients in Australia.

These extracts will be provided to researchers and prescribing clinicians to investigate, understand and optimise the therapeutic effectiveness of medicinal cannabis for specific medical conditions.

Through relationships with organisations both in Australia and overseas, Cann has obtained elite genetic materials to locally develop specific genetic strains by utilising advanced breeding programs.

Cann intends to be a leading developer and supplier of cannabis, cannabis resin and medicinal cannabis products.

 
 
Cann aims to cultivate and manufacture a range of medicinal cannabis products for patients in Australia.

 

INVESTOR

Cann is the first Australian company to secure the necessary licences to undertake research and to cultivate cannabis for human medicinal and research purposes.

RESEARCHER

Australian laws have recently changed to allow for legal research into the therapeutic benefits of cannabis.

Learn More

CLINICIAN

Since 2016, authorised patients have been legally permitted to use cannabis extracts where considered appropriate for the treatment of a range of chronic medical conditions.

Learn More

PATIENT

People have been using cannabis for its therapeutic benefits for a long time.

Learn More
 

 

Shining light on medicinal cannabis